Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Anngeen Technolgies Raises $14 Million for Clinical Genetic Diagnosis Operations

publication date: Feb 19, 2020

Anngeen Technologies of Beijing raised more than $14 million in a Series B financing to support its gene sequencing services for clinical diagnosis. The company has set up at least 10 centers in partnership with hospitals to apply next-gen sequencing and bioinformatics to diagnose hereditary diseases in cardiovascular, kidney, blood and hereditary cancer conditions. It also provides individualized medication guidance and tumor molecular detection along with in vitro diagnostic kits. Anngeen wants to become the world's leading provider of genetic disease detection services. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020